Learn how bronchiectasis affects more than just your lungs, from heart health and bone density to mental well-being and cognitive risks.

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis ...

BRESSO, Italy--(BUSINESS WIRE)--Zambon announced that colistimethate sodium powder for nebulizer solution, delivered by the I-neb AAD system obtained QIDP and “Fast Track” designation by the FDA for ...

BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...

Insmed’s fair value estimate has been fine tuned, with the modeled price target edging from US$212.53 to US$213.00, signaling only a very modest shift in the equity story. That small adjustment lines ...